A small-molecule-inhibitor of WEE1, AZD1775 as a chemosensitizing agent in acute leukemia
MetadataShow full item record
Although some patients with acute leukemia have good prognoses, the prognosis of adult and pediatric patients who relapse or cannot tolerate standard chemotherapy is poor. Thus, novel therapies are necessary to improve outcomes in acute leukemia. Conventional chemotherapy is the mainstay of treatment for acute leukemia, and one approach to improving outcomes is to enhance the efficacy of these drugs. Inhibition of the cell cycle protein WEE1 has been shown to enhance the efficacy of a number of conventional chemotherapy agents by abrogating cell cycle arrest, increasing DNA damage accumulation, ...